Victory Capital Management Inc. Boosts Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Victory Capital Management Inc. boosted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 300.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,871 shares of the biopharmaceutical company’s stock after purchasing an additional 51,671 shares during the quarter. Victory Capital Management Inc.’s holdings in Ocular Therapeutix were worth $588,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. HighVista Strategies LLC boosted its position in shares of Ocular Therapeutix by 5.1% in the 3rd quarter. HighVista Strategies LLC now owns 65,027 shares of the biopharmaceutical company’s stock valued at $566,000 after purchasing an additional 3,168 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Ocular Therapeutix by 11.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company’s stock valued at $285,000 after purchasing an additional 3,347 shares in the last quarter. Rhumbline Advisers increased its stake in Ocular Therapeutix by 2.7% in the 4th quarter. Rhumbline Advisers now owns 213,601 shares of the biopharmaceutical company’s stock valued at $1,824,000 after purchasing an additional 5,682 shares in the last quarter. Palumbo Wealth Management LLC purchased a new position in Ocular Therapeutix in the 4th quarter valued at approximately $100,000. Finally, The Manufacturers Life Insurance Company increased its stake in Ocular Therapeutix by 11.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 130,202 shares of the biopharmaceutical company’s stock valued at $1,133,000 after purchasing an additional 13,238 shares in the last quarter. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Stock Up 0.9 %

Shares of OCUL opened at $7.51 on Friday. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -5.69 and a beta of 1.34. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a 12 month low of $4.06 and a 12 month high of $11.78. The company has a 50-day moving average price of $7.57 and a two-hundred day moving average price of $8.78.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The company had revenue of $17.08 million during the quarter, compared to the consensus estimate of $16.89 million. Equities analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

OCUL has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Needham & Company LLC began coverage on Ocular Therapeutix in a research report on Tuesday, March 11th. They issued a “buy” rating and a $15.00 target price for the company. JMP Securities set a $19.00 price target on Ocular Therapeutix in a report on Tuesday, March 4th. Finally, Royal Bank of Canada assumed coverage on Ocular Therapeutix in a research note on Tuesday. They set an “outperform” rating and a $17.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Ocular Therapeutix has a consensus rating of “Moderate Buy” and an average target price of $16.38.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the sale, the insider now directly owns 3,520,318 shares of the company’s stock, valued at $24,184,584.66. The trade was a 0.61 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Donald Notman sold 11,119 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the sale, the insider now directly owns 193,444 shares in the company, valued at $1,510,797.64. This trade represents a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,895 shares of company stock valued at $283,772. Company insiders own 3.50% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.